Corporate Presentation
Obesity
Petrelintide
Petrelintide is a potential best-in-class amylin analog
for GLP-1RA-like weight loss with better tolerability
Design of molecule
Petrelintide (ZP8396) is a 36-amino-acid acylated peptide,
based on the peptide sequence of human amylin
ZEAL&
ZEALAND PHARMA
Positioning opportunities and differentiation
Long-acting amylin analog (half-life of 10 days)¹,
suitable for once-weekly administration
Obesity - targeting GLP-1RA-like weight loss with
high quality, incl. preservation of muscle mass
Chemical and physical stability at neutral pH,
allowing for co-formulation with other peptides²
MoA - alternative mechanism that reduces food intake
by restoring leptin sensitivity and increasing satiety
Potent agonistic effects on amylin and
calcitonin receptors³
Safety and tolerability - potential for better
tolerability vs GLP-1RAS
Sources: 1. Olsen et al. Poster 92-LB. Presented at ADA 83rd Scientific Sessions, June 23-26, 2023, San Diego, CA; 2. Skarbaliene et al. Poster 1406-P. Presented at ADA 82nd Scientific Sessions, June 3-7, 2022, New Orleans, LA;
3. Eriksson et al. Presentation at ObesityWeek, November 1-4, 2022, San Diego, CA.
GLP-1RA-glucagon-like peptide-1 receptor agonist; MOA=mechanism of action.
Intellectual property: Composition of matter, patent expiry in 2037. Patent-term extension up to 5 years, i.e. 2042. Potential rights beyond 2042 based on patent applications and additional elements.
12View entire presentation